
Roche's drug is one of a number competing to become the first Bruton's kinase inhibitors approved as a treatment for multiple sclerosis.

Roche's drug is one of a number competing to become the first Bruton's kinase inhibitors approved as a treatment for multiple sclerosis.

The data revealed that 17.1% of patients experienced grade 3 or greater arrhythmias.

Data from the DEVOTE study suggest that 50-milligram doses are safe and effective.

Insight into nocturnal hot flash timing could provide clues about heart disease risk in perimenopausal women.

Researchers that clinical guidelines highlight the possibility of chronic obstructive pulmonary disease and other conditions masking early symptoms of lung cancer.

Lebrikizumab, not yet approved in the U.S., and Dupixent (dupilumab) were comparably effective in reducing symptoms after 16 weeks of treatment.

Kristi Funk, M.D., FACS, medical director and co founder of the Pink Lotus Breast Center, describes why there is a lack of awareness surrounding the link between breast cancer and nutrition.

The IQVIA vice president and frequent speaker at pharmaceutical and managed care meetings shares some insights after he delivered the keynote talk at 2024 PBMI Annual National Conference held last week in Orlando, Florida. Long, a well-known figure in managed care circles, announced at the PBMI meeting that he is retiring in 2025.

The rule places new requirements on plans, including making sure prior authorization and other utilization management tools for mental health are not stricter than those used for medical benefits.

Women with disadvantaged backgrounds may also benefit more than women with a higher socioeconomic status, study results show.

Kerri Tanner, Pharm.D., chief pharmacy officer of PayerAlly, discusses the dynamic pricing models of Waltz Health and Free Market Health as a way for independent specialty pharmacies to compete.

The researchers took what they said was a conservative approach when plugging variables such as one-time and future costs into their updated model.

Many provisions of the Affordable Care Act are popular and the healthcare reform law has brought the proportion of Americans without healthcare insurance down to an all-time low. As president, Donald Trump backed "repeal and replace" efforts.

Entyvio (vedolizumab) and Xeljanz (tofacitinib) are the most commonly studied therapies, according to the Pfizer-sponsored review, and when the two were compared, Xeljanz showed higher remission rates.

The two clinical trials will enroll patients recovering from surgical procedures.

Here's what you missed this week on Managed Healthcare Executive.


Kerri Tanner, Pharm.D., the chief pharmacy officer of PayerAlly, says payers are looking for ways to rein in the escalating costs of specialty pharmacy drugs beyond the traditional techniques used by pharmacy benefit managers.

Patrick Cooney, president of The Federal Group, says elimination of spread pricing is one of the three key elements of the PBM legislation that he believes is likely to pass during the lame-duck session of Congress after the Nov. 5 election.

Greg Baker, CEO of AffirmedRx, did not hold back in criticizing CVS Caremark, Optum Rx and Express Scripts and their group purchasing organizations today at the PBMI Annual National Conference.

Patrick Cooney, president of The Federal Group, a Washington, D.C., lobbying firm says prospects for legislation passing this year, albeit during the post-election lameduck session, are good partly because the PBM legislation would produce Medicare savings that could be put toward other uses.

Telehealth has become a permanent part of U.S. healthcare delivery, and states are taking steps to regulate it

The IQVIA vice president and frequent speaker at pharmacy and managed care meetings said he will retire in May 2025.

HIV treatments using a single pill improve adherence and are cheaper to maintain.

Pharmacy benefit managers aren't getting mentioned on the campaign trail, but there are some signs Congress could enact reform legislation after the Nov. 5 election.

Joseph Shields of TransparencyRx predicts there will be more lawsuits against self-funded employers alleging they’ve mismanaged prescription drug benefits through PBMs.

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

Breast cancer patients were also less likely to have a breast reconstruction than patients living elsewhere.

A nomogram based on four pulmonary factors is helpful but not a substitute for clinical judgment, say the authors.

Reproductive rights and abortion: The hottest healthcare issue